This site is intended for US audiences only.

RESULTS WITH OPTUNE PAX®

In a clinical trial, Optune Pax was studied in 571 people with locally advanced pancreatic cancer. Half of those people used Optune Pax together with cancer drugs called gemcitabine and nab-paclitaxel, while the other half only used cancer drugs without Optune Pax.*

*Cancer drugs=gemcitabine and nab-paclitaxel.

Actor portrayal.

In a large clinical study of adult patients with locally advanced pancreatic cancer

People using Optune Pax® lived 2 months longer

People using Optune Pax with cancer drugs lived 2 months longer, on average, than people using only cancer drugs.*

~68% of people were still living at 1 year

when using Optune Pax with cancer drugs compared to 60.2% of people using only cancer drugs.*

In a subset of patients in the clinical trial (405 out of 571) who stayed on therapy for at least 28 days

People using Optune Pax lived 3 months longer

People using Optune Pax with cancer drugs lived 3 months longer, on average, than people using only cancer drugs.*

~75% of people were still living at 1 year

when using Optune Pax with cancer drugs compared to 65.9% of people using only cancer drugs.*

People treated with Optune Pax and cancer drugs experienced a delay in time to their pain getting worse compared to people treated with cancer drugs alone.*

Optune Pax with cancer drugs did not negatively impact patients' quality of life versus cancer drugs alone*†

The group treated with Optune Pax and cancer drugs experienced better quality of life from the start of treatment until a significant health deterioration change was observed. Overall, they experienced a delayed onset of health deterioration, pain, and pancreatic pain.

*Cancer drugs=gemcitabine and nab-paclitaxel.

†Based on the European Organisation for Research and Treatment of Cancer (EORTC) core quality of life questionnaire. Data was collected for 26 months.

Skin irritation was the most common device-related side effect in the clinical trial of Optune Pax

Learn more

Indication and Important Safety Information

What is Optune Pax® approved to treat?

Optune Pax is an FDA-approved, wearable therapeutic device, used together with gemcitabine and nab-paclitaxel (a chemotherapy combination). It is indicated for the treatment of adult patients with locally advanced pancreatic cancer.

Who should not use Optune Pax?

Optune Pax for locally advanced pancreatic cancer is not for everyone. Talk to your doctor if you have:

  • An electrical implant. Use of Optune Pax together with electrical implants has not been tested and may cause the implanted device not to work properly
  • A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing

Do not use Optune Pax if you are pregnant or are planning to become pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. It is not known if Optune Pax is safe or effective during pregnancy.

What should I know before using Optune Pax?

Optune Pax should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Pax.

  • Do not use any parts that did not come with the Optune Pax Treatment Kit sent to you by Novocure or given to you by your doctor
  • Do not get the device or transducer arrays wet
  • Please be aware that Optune Pax has a cord that plugs into an electrical socket. Be careful of tripping when it's connected
  • If you have an underlying skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Pax treatment

What are the possible side effects of Optune Pax?

The most common side effects of Optune Pax used together with chemotherapy drugs were low neutrophils, low red blood cell count, low platelet count, low white blood cell count, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, swelling, fever, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, liver enzyme increased, weight loss, low potassium level, low albumin level, high blood sugar, muscle pain, neuropathy peripheral (damage to the nerves outside the brain and spinal cord), taste disorder, dizziness, difficulty sleeping, shortness of breath, hair loss, skin-related disorders, and low blood pressure.

Device-related skin adverse effects associated with the use of Optune Pax include skin inflammation, rash, itching, flat or raised spots, skin redness, skin irritation, skin reaction, and open sores. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays. Talk to your doctor if you have any of these side effects or have any questions.

Please see the full Patient Information and Operation Manual (PIOM) for Optune Pax at OptunePax.com.

 

Indication and Important Safety Information

What is Optune Pax® approved to treat?

Optune Pax is an FDA-approved, wearable therapeutic device, used together with gemcitabine and nab-paclitaxel (a chemotherapy combination). It is indicated for the treatment of adult patients with locally advanced pancreatic cancer.

Who should not use Optune Pax?

Optune Pax for locally advanced pancreatic cancer is not for everyone. Talk to your doctor if you have:

  • An electrical implant. Use of Optune Pax together with electrical implants has not been tested and may cause the implanted device not to work properly
  • A known sensitivity to gels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes. In this case, skin contact with the gel used with Optune Pax may commonly cause increased redness and itching. In rare cases, it may lead to severe allergic reactions that can cause a drop in blood pressure and difficulty breathing

Do not use Optune Pax if you are pregnant or are planning to become pregnant. If you are a woman who is able to get pregnant, you must use birth control when using the device. It is not known if Optune Pax is safe or effective during pregnancy.

What should I know before using Optune Pax?

Optune Pax should only be used after receiving training from qualified personnel, such as your doctor, a nurse, or other medical staff who have completed a training course given by Novocure®, the maker of Optune Pax.

  • Do not use any parts that did not come with the Optune Pax Treatment Kit sent to you by Novocure or given to you by your doctor
  • Do not get the device or transducer arrays wet
  • Please be aware that Optune Pax has a cord that plugs into an electrical socket. Be careful of tripping when it's connected
  • If you have an underlying skin condition where the transducer arrays are placed, discuss with your doctor whether this may prevent or temporarily interfere with Optune Pax treatment

What are the possible side effects of Optune Pax?

The most common side effects of Optune Pax used together with chemotherapy drugs were low neutrophils, low red blood cell count, low platelet count, low white blood cell count, diarrhea, nausea, vomiting, abdominal pain, constipation, fatigue, swelling, fever, pain, COVID-19, infection, respiratory tract infection, urinary tract infection, pneumonia, liver enzyme increased, weight loss, low potassium level, low albumin level, high blood sugar, muscle pain, neuropathy peripheral (damage to the nerves outside the brain and spinal cord), taste disorder, dizziness, difficulty sleeping, shortness of breath, hair loss, skin-related disorders, and low blood pressure.

Device-related skin adverse effects associated with the use of Optune Pax include skin inflammation, rash, itching, flat or raised spots, skin redness, skin irritation, skin reaction, and open sores. Other device-related adverse effects associated with the use of Optune Pax include overheating of the array, leading to pain and/or local skin burns, allergic reaction to the adhesive or gel from the transducer arrays, and local warmth and tingling sensation beneath the arrays. Talk to your doctor if you have any of these side effects or have any questions.

Please see the full Patient Information and Operation Manual (PIOM) for Optune Pax at OptunePax.com.

 

Novocure websites

This website is intended only for US audiences seeking information on Optune Pax.

©2026 Novocure GmbH. All Rights Reserved.  

Optune, Optune Pax, MyNovocure, and Novocure are registered trademarks of Novocure GmbH.  

All other trademarks, registered or unregistered, are the property of their respective owners.


US-OPP-00008 v1.0 April 2026